Pharmafile Logo

Ultibro Breezhaler

- PMLiVE

Avastin safe in eye disease, says Cochrane

Recommends off-label use of Roche drug as cheaper alternative to Novartis’ Lucentis

- PMLiVE

Mixed messages for AZ’s benralizumab in COPD study

Respiratory hope misses primary goal in trial data presented at ERS congress

- PMLiVE

Boehringer’s Spiriva cleared for asthma in EU

Drug approved as a treatment for adults with severe asthma

- PMLiVE

Pharma and med tech companies form eye health group

The Industry Vision Group wants the NHS to make eye care a priority

Novartis building

Novartis’ Ultibro tops Seretide in comparative COPD trial

Will help Novartis position Ultibro as a corticosteroid-free alternative to GSK's blockbuster

Novartis building

Novartis heart failure trial leads the buzz at ESC

Potential blockbuster LCZ696 cuts cardiovascular deaths by 20% versus standard therapy

Novartis building

Novartis licenses tuberculosis R&D to TB Alliance

Includes drugs to tackle resistant forms of the disease

- PMLiVE

GSK relaunches COPD website

Revamped online hub offers tools and guidance for those affected by respiratory condition

Novartis building

Novartis will file heart failure drug before year-end

New data reinforces view that LCZ696 can reduce cardiovascular deaths

Novartis building

Novartis: novel antimalarial is ‘game-changing’

Says cipargamin could be first new class of malaria drugs in 20 years

- PMLiVE

AstraZeneca signs $2bn deal to buy Almirall respiratory portfolio

Will boost its pipeline prospects and inhaled device capabilities

Novartis building

Novartis’ glaucoma combo cleared in Europe

Simbrinza approved to treat eye condition

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links